\"Novus ordo seclorum\": new applications af monoclonal antibodies in breast cancer
Journal Title: Współczesna Onkologia - Year 2005, Vol 9, Issue 10
Abstract
Trastuzumab (Herceptin) is a recombinant humanized monoclonal IgG1 antibody inhibiting selectively HER2 receptor in tumour cells, that has found a clinical application in breast cancer treatment. Until recently, this compound has been used exclusively in advanced breast cancer patients. During the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) preliminary results of three large randomized studies were presented in which trastuzumab in combination with chemotherapy was administered in the adjuvant setting in operable breast cancer patients with HER2 expression or amplification. Two of these studies (NSABP-31 and NCCTG-N9831) were performed by the American cooperative groups: the National Surgical Adjuvant Breast and the Bowel Project (NSABP) and the North Central Cancer Treatment Group (NCCTG), and the third one (HERA) was a global enterprise coordinated by the Breast Intergroup (BIG) in Brussels. The presented results demonstrated a surprisingly positive impact of trastuzumab: the relative risk of disease failure was halved and additionally, in the two American studies the risk of death was significantly reduced. The treatment was well tolerated and the only serious adverse side effect was an increased risk of cardiotoxicity. At the same session, results of the first study of the third phase were presented showing a significant increase of time to progression associated with the addition of antiangiogenic monoclonal antibody – bevacizumab to standard chemotherapy of advanced breast cancer. This article presents the result of these studies and discusses their potential implications on changing standards of care in breast cancer.
Authors and Affiliations
Renata Duchnowska, Cezary Szczylik
Keywords
Related Articles
- EP ID EP139063
- DOI -
- Views 68
- Downloads 0
The role of endocrine therapy in adjuvant management for premenopausal breast cancer patients
The efficacy of adjuvant treatment in some cases of early breast cancer is unquestionable. In 1998, the first report about the role of adjuvant treatment was published. Opinion leaders, such as the International Expert...
Pierwotne nowotwory złośliwe języka
Nowotwory złośliwe języka występują stosunkowo często. Rak płaskonabłonkowy stanowi prawie 95% nowotworów złośliwych części twarzowej czaszki, zaś w obrębie błony śluzowej jamy ustnej 40% to raki języka. Łagodne nowotwor...
Hemangioblastoma of the cervical part of the spinal cord in the course of von Hippel-Lindau syndrome
A 37-year-old patient was irradiated after a subtotal excision of the hemangioblastoma of the cervical spinal cord. On the basis of history, physical examination and performed additional tests, the diagnosis of VHL syndr...
Leczenie uzupełniające raka jelita grubego
Utylizacja radu 226 z ośrodka onkologicznego – ocena narażenia personelu
226Ra znalazł zastosowanie w terapii onkologicznej ze względu na długi okres połowiczego rozpadu i rodzaj emitowanego promieniowania. Po wielu latach stosowania zastąpiono go izotopami krótkożyciowymi, charakteryzujący...